Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
This study has been completed.
Sponsor:
AbbVie (prior sponsor, Abbott)
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT00648999
First received: March 28, 2008
Last updated: March 14, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Human Immunodeficiency Virus |
Drug: lopinavir/ritonavir |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra |
Resource links provided by NLM:
Further study details as provided by AbbVie:
Primary Outcome Measures:
- Quality of Life [ Time Frame: Baseline, Week 4, Week 24 and Week 48 ] [ Designated as safety issue: No ]
- CD4 [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Adverse Event Monitoring [ Time Frame: Baseline, Week 4, Week 24 and Week 48 ] [ Designated as safety issue: Yes ]
| Enrollment: | 207 |
| Study Start Date: | November 2003 |
| Study Completion Date: | December 2006 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 |
Drug: lopinavir/ritonavir
lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
Other Names:
|
| Active Comparator: 2 |
Drug: lopinavir/ritonavir
lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
Other Names:
|
Eligibility| Ages Eligible for Study: | 17 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HIV Infected subjects
- Subjects failing in current HIV treatment, or
- Subjects with a viral load < 400 copies/mL and not tolerating their current HIV treatment.
Exclusion Criteria:
- Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit
- Subject is pregnant
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648999
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648999
Locations
| Mexico | |
| Site Ref # / Investigator 4049 | |
| Mexico City, Distrito Federal, Mexico, 01030 | |
| Site Ref # / Investigator 4050 | |
| Mexico City, Distrito Federal, Mexico, 01120 | |
| Site Ref # / Investigator 4051 | |
| Mexico City, Distrito Federal, Mexico, 09220 | |
| Site Ref # / Investigator 4056 | |
| Mexico City, Distrito Federal, Mexico | |
| Site Ref # / Investigator 4077 | |
| Mexico City, Distrito Federal, Mexico, 10300 | |
| Site Ref # / Investigator 4074 | |
| Leon, Guanajauto, Mexico | |
| Site Ref # / Investigator 4054 | |
| Morelia, Michoacan, Mexico | |
| Site Ref # / Investigator 4072 | |
| Tepic, Nayarit, Mexico | |
| Site Ref # / Investigator 4055 | |
| Culiacan, Sinaloa, Mexico | |
| Site Ref # / Investigator 4075 | |
| Merida, Yucatan, Mexico, 97219 | |
| Site Ref # / Investigator 4073 | |
| Chihuahua, Mexico, 31310 | |
| Site Ref # / Investigator 4052 | |
| Oaxaca, Mexico | |
| Site Ref # / Investigator 4053 | |
| Puebla, Mexico, 72570 | |
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
| Study Director: | Jose Canadas, MD | AbbVie |
More Information
Additional Information:
No publications provided
| Responsible Party: | AbbVie ( AbbVie (prior sponsor, Abbott) ) |
| ClinicalTrials.gov Identifier: | NCT00648999 History of Changes |
| Other Study ID Numbers: | MEXI-P01-02 |
| Study First Received: | March 28, 2008 |
| Last Updated: | March 14, 2013 |
| Health Authority: | Mexico: Federal Commission for Protection Against Health Risks |
Keywords provided by AbbVie:
|
Kaletra |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Virus Diseases |
Lopinavir Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antiviral Agents Enzyme Inhibitors HIV Protease Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protease Inhibitors Therapeutic Uses |
ClinicalTrials.gov processed this record on March 03, 2015